UCB, Inc.BIMZELXTwo 160 mg/mL in single-dose autoinjectors
Indications and Usage
INDICATIONS AND USAGE
BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of:
- Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy.
- Adults with active psoriatic arthritis (PsA) .
- Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation.
- Adults with active ankylosing spondylitis ( AS ).
- Adults with moderate to severe hidradenitis suppurativa (HS) .
Plaque Psoriasis
BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Psoriatic Arthritis
BIMZELX is indicated for the treatment of adults with active psoriatic arthritis.
Non-Radiographic Axial Spondyloarthritis
BIMZELX is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.
Ankylosing Spondylitis
BIMZELX is indicated for the treatment of adults with active ankylosing spondylitis.
Hidradenitis Suppurativa
BIMZELX is indicated for the treatment of adults with moderate to severe hidradenitis suppurativa.
FAQsAll you need to know to order samples
Due to manufacturer restrictions, there are some limitations on the quantities of samples that can be included in each order. We're working on new functionality to let your practice place larger, batch orders.